Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc., (APUSA) has successfully completed its acquisition of Lannett Company, Inc., USA (Lannett), from Lannett Seller Holdco, Inc., following receipt of approval from the U.S. Federal Trade Commission on June 18, 2026. Lannett has become a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC.
The integration process will commence immediately, with a strong emphasis on ensuring uninterrupted access to critical medications, maintaining trusted relationships with partners, and supporting employees throughout the transition. By combining capabilities and resources, the organization aims to enhance the availability of essential medicines and deliver sustained, long-term value to patients, customers, and stakeholders.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
